Recent U.S. policy work has focused on reimbursement, provider payment and the cost of delivering psychedelic-assisted care.
What the authors examined
Two recent policy analyses looked at how psychedelic-assisted therapies could fit into the U.S. healthcare system if they become more widely available. They focused on reimbursement, provider roles, treatment costs and Medicaid.
What the authors argue
A 2025 JAMA Health Forum viewpoint identified gaps in U.S. policy infrastructure around psychedelic therapies, including reimbursement, professional roles, facility costs and coordination across agencies.
The authors proposed options including bundled reimbursement for the full treatment pathway, Medicaid demonstration programs and a broader public-private framework for best practices.
A 2026 Center for Health Care Strategies brief examined similar issues through Medicaid, drawing on research and interviews with Medicaid stakeholders.
What this helps us understand
These analyses shift the access question from whether psychedelic therapies may become available to how a full course of care could be financed and delivered. Reimbursement, provider payment, facilities and coordination all become part of the access picture. For policy and health-system teams, those operational questions are part of understanding how a treatment could work in practice.
These are policy analyses. The approaches described are proposals, not current coverage requirements.
